Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma
Cancer Medicine · 2023
DOI: 10.1002/cam4.5955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yang Wo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Mesothelioma, Malignant, Mesothelioma, Pleural Neoplasms, Lung Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Objectives
The role of postoperative radiotherapy (PORT) in malignant pleural mesothelioma (MPM) remains controversial and the eighth edition TNM staging scheme for MPM has not been fully verified. We aimed to develop an individualized prediction model for identifying optimal candidates for PORT among MPM patients who received surgery plus chemotherapy and externally validate the performance of the new TNM staging scheme. Materials and Methods Detailed characteristics of MPM patients during 2004–2015 were retrieved from SEER registries. Propensity score matching (PSM) was conducted to reduce disparities of baseline characteristics (age, sex, histologic type, stage, and type of surgery) between the PORT group and no‐PORT group. A novel nomogram was constructed based on independent prognosticators identified by multivariate Cox regression model. The discriminatory performance and degree of calibration were evaluated. We stratified patients into different risk groups according to nomogram total scores and estimated the survival benefit of PORT in different subgroups in order to identify the optimal candidates.
Results
We identified 596 MPM patients, among which 190 patients (31.9%) received PORT. PORT conferred significant survival benefit in the unmatched population, while there was no significant survival difference favoring PORT in the matched population. The C‐index of the new TNM staging scheme was closed to 0.5, which represented a poor discriminatory ability. A novel nomogram was constructed based on clinicopathological factors, including age, sex, histology, and N stage. We stratified patients into three risk groups. Subgroup analyses indicated that PORT was beneficial for high‐risk group ( p = 0.003) rather than low‐risk group ( p = 0.965) and intermediate‐risk group ( p = 0.661).
Conclusion
We established a novel predictive model, which could make individualized prediction of survival benefit of PORT for MPM and could compensate for weakness in TNM staging system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
- Institute of Thoracic Oncology, Fudan University, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Yang Wo
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Wo, Y., Peng, Y., Wu, Z., Liu, P., Shang, Y., Shen, X., & Sun, Y. (2023). Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma. Cancer Medicine. https://doi.org/10.1002/cam4.5955
Vancouver
Wo Y, Peng Y, Wu Z, Liu P, Shang Y, Shen X, et al. Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma. Cancer Medicine. 2023. doi:10.1002/cam4.5955
BibTeX
@article{Wo2023,
author = {Wo, Yang and Peng, Yizhou and Wu, Zhigang and Liu, Pengcheng and Shang, Yan and Shen, Xuxia and Sun, Yihua},
title = {Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5955}
}
EUVIMED